ESR1 and breast cancer: The CDK 4/6 inhibitor, palbociclib, in combination with other drugs, has been approved by the FDA to treat metastasized breast cancer that is estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (Ciruelos et al., 2020).